Get the Stockscreener App
1.36
0.73%
-0.01
Soligenix Inc stock is traded at $1.36, with a volume of 363.19K.
It is down -0.73% in the last 24 hours and down -28.80% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.37
Open:
$1.37
24h Volume:
363.19K
Relative Volume:
4.67
Market Cap:
$6.10M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.1799
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
-20.00%
1M Performance:
-28.80%
6M Performance:
-52.94%
1Y Performance:
-48.68%
1-Day Range:
$1.3205
$1.52
1-Week Range:
$1.31
$1.77
52-Week Range:
$1.31
$14.83
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.36 | 6.10M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix Inc. Advances in Treatment for Behçet’s Disease with SGX945 - citybuzz -
Soligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease - The Globe and Mail
Behcet's Disease Market Growth to Accelerate in Forecast Period - openPR.com
Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com
True North Commercial REIT Announces June 2025 Distribution - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Makes Strides in Rare Disease Treatments with Upcoming Clinical Trial Results - citybuzz -
Silicon Valley - FinancialContent
Soligenix (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL - Barchart.com
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise - GuruFocus
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials | SNGX Stock News - GuruFocus
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewswire
Soligenix Inc. (SNGX) Showcases Promising HyBryte Results in CTCL Treatment Through New Podcast - citybuzz -
Soligenix (NASDAQ: SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim - Barchart.com
Soligenix (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics - Barchart.com
Vaccine Contract Manufacturing Market Is Booming Worldwide | - openPR.com
Galaxy Digital Inc. Announces Public Offering of Common Stock - The Globe and Mail
Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results In Rare Cancer Trial - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial - The Globe and Mail
Chemung Financial Corporation Announces Quarterly Dividend - The Globe and Mail
Soligenix’s HyBryte Shows Promise in Rare Cancer Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results - The Globe and Mail
/R E P E A T -- Scotiabank to Announce Second Quarter 2025 Results/ - The Globe and Mail
Public market insider selling at Sprott (SII) - The Globe and Mail
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Zacks Small Cap Predicts Reduced Earnings for Soligenix - Defense World
Zacks Research Issues Business Update as Soligenix (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial - The Globe and Mail
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN
Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree
Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq
Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus
Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response - FinancialContent
Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com
Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com
Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India
Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance
Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):